| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | SECOND GENOME, INC. | 1000 MARINA BLVD STE 500 | BRISBANE | CA | 94005-1838 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 000 | 3 | NIH | 5/5/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | SECOND GENOME, INC. | 1000 MARINA BLVD STE 500 | BRISBANE | CA | 94005-1838 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 001 | 3 | NIH | 7/15/2021 | $0 |
| | 2021 | 2020 | SECOND GENOME, INC. | 1000 MARINA BLVD STE 500 | BRISBANE | CA | 94005-1838 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 000 | 3 | NIH | 5/6/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $967,251 ) |
| | 2020 | 2020 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 000 | 3 | NIH | 1/6/2020 | $967,251 |
|
| Issue Date FY: 2019 ( Subtotal = $977,355 ) |
| | 2019 | 2019 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 000 | 2 | NIH | 1/14/2019 | $859,193 |
| | 2019 | 2019 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 003 | 2 | NIH | 7/11/2019 | $149,499 |
| | 2019 | 2019 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 001 | 2 | NIH | 1/28/2019 | $118,162 |
| | 2019 | 2017 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 002 | 1 | NIH | 7/11/2019 | -$149,499 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2017 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 000 | 1 | NIH | 4/4/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $149,499 ) |
| | 2017 | 2017 | SECOND GENOME, INC. | 341 ALLERTON AVE | SOUTH SAN FRANCISCO | CA | 94080-4816 | SAN MATEO | USA | R44DA043954 | Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders | 000 | 1 | NIH | 6/29/2017 | $149,499 |
|
|
